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1. INTRODUCTION 
 
      Amongst the various routes of drug delivery, oral route is 
perhaps the most preferred to the patient and the clinicians alike. 
However, peroral (Jain, 2003) administrations of drugs have 
disadvantages such as hepatic first-pass metabolism and enzymatic 
degradation within the GI, which that prohibits oral administration of 
certain classes of drugs. 
 
Consequently, other absorptive mucosae are considered as 
potential sites for drug administration. Transmucosal routes of drug 
delivery (i.e., mucosal linings of the nasal, rectal). 
 
 Buccal Delivery system 
 Oral Delivery System 
 Vaginal delivery system 
 Rectal delivery system 
 Nasal Delivery System 
 Occular Delivery system 
 
1.1 FUNDAMENTALS OF BIOADHESION 
Development of an adhesive bond b/w a polymer and 
biological membrane or its coating can be visualized as a 2-step 
process. (Lenaerts et al., 1990). 
 
 Step 1 – Initial contact b/w the 2 surfaces 
 Step 2 – Formation of secondary bonds due to non-covalent 
interaction.  
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          This process of bond formation attributed to surface of the 
biological membrane, surface of the adhesive and the interfacial 
layer between the two surfaces. Molecular events that take place in 
the interfacial layer depend on the properties of the polymer and 
membrane. 
 
Bioadhesive polymers 
Bioadhesive polymers are classified into 2 main categories. 
1. Polymers that are water soluble, linear and random polymer 
2. Water insoluble compounds that has swellable networks 
joined by cross-linking agents. 
 
There are so many properties associated with bioadhesive 
property of polymers. 
 
 Molecular weight, chain length and cross-linking density 
 Charges and Ionization 
 Hydrophilic group and hydration 
 Chain segment mobility 
 
1.2 MECHANISM OF BIOADHESION 
 
Several theories of bioadhesion have been proposed to explain 
fundamental mechanisms of attachment (Deryaguin et al., 1997). 
 
a. Electronic theory 
The adhesive polymer and mucus typically have different 
electronic characteristics when there two surfaces come in contact, a 
double layer of electrical charges form of the interface and then 
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adhesion develops due to the attractive force from e Transfer across 
the electrical double layer. 
 
b. Adsorption Theory 
In the adsorption theory, a bioadhesive polymer adheres to 
mucus because of two surface forces such as Vander Waals’ forces, 
hydrogen bonds or hydrophobic interactions (Kaelbe, 1997). 
 
c. Wetting Theory 
Wetting Theory is predominantly applicable to liquid 
bioadhesive systems and analyses adhesive and contact behavior in 
terms of the ability of a liquid or a paste to spread over a biological 
system. 
 
The work of adhesion, ‘Y’ being defined as the energy per 
cm2 released when an interface is formed. The work of adhesion is 
given by: 
Wa = YA + YB + YAB 
  
where A, B refers to biological membrane and the bioadhesive 
formulation, respectively.  
 
d. Diffusion Theory 
 
The essence of this theory is that chains of the adhesive and 
the substrate interpenetrate one another to a sufficient depth to create 
a semi permanent adhesive bond, the penetration rate depends on the 
diffusion coefficients of both interacting polymers and the diffusion 
coefficient is known to depend on molecular weight and cross 
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linking density. (Champion, 1975; Wake, 1978). In addition, 
segment mobility, flexibility of the bioadherive polymer, mucus 
glycoprotein and the expanded nature of both networks are important 
parameters that need to be considered. Drug delivery via the 
membrane of the oral cavity can be subdivided as follows: 
 
1. Sublingual delivery – which is the administration of drug via the 
sublingual mucosae (The membrane of the ventral surface of the 
tongue and the floor of the mouth) to the systemic circulation. 
2. Buccal delivery - which is the administration of drug via the 
buccal mucosa (the lining of the cheek) to the systemic 
circulation. 
3. Local delivery – For the treatment of conditions of the oral 
cavity, principally for ulcers, fungal conditions periodontal 
disease. 
 
1.3 ADVANTAGES OF BUCCAL DRUG DELIVERY SYSTEM 
 
Drug administration via the oral mucosae offers several 
advantages, (Khanna et al., 1998). 
 
1. Ease of administration 
2. Termination of therapy is easy 
3. Permit localization of the drug to the oral cavity for a 
prolonged period of time. 
4. Can be administered to unconscious patients 
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5. Offers an excellent route for the systemic delivery of drugs 
with high first pass metabolism, thereby offering a greater 
bioavailability. 
6. A significant reduction in dose can be achieved thereby 
reducing dose dependent side effects. 
7. Drugs which are unstable in the acidic environment are 
destroyed by the enzymatic or alkaline environment of the 
intestines can be administered by this route. 
8. Drugs which show poor bioavailability via the oral route can 
be administered conveniently. 
9. It offers a passive system for drug absorption and does not 
require any activation. 
10. The presence of saliva ensures relatively less amount of water 
for drug dissolution unlike in case of rectal and transdermal 
routes. 
11. Systemic absorption is rapid. 
12. This route provides an alternative for the administration of 
various hormones, narcotic analgesic, steroids, enzymes, 
cardiovascular agents, etc. 
13. The buccal mucosa is highly perfused with blood vessels and 
offers a greater permeability than the skin. 
14. It allows for the local modification of tissue permeability, 
inhibition of protease activity or reduction in immunogenic 
response. Thus, relative use of therapeutic agents like 
peptides, protein and ionized species can be achieved. 
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15. Therapeutic return concentration of the drug can be achieved 
more rapidly. 
 
1.4 LIMITATIONS OF BUCCAL DRUG ADMINISTRATION 
Drug administration via this route has certain limitations 
(Khanna et al., 1998) 
1. Drug, which irritate the mucosa or have a bitter or unpleasant 
taste or an obnoxious odor, cannot be administered by this 
route. 
2. Drugs, which are unstable at buccal pH, cannot be 
administered by this route. 
3. Only drugs with small dose requirements can be administered. 
4. Drug contained in the swallowed saliva follows the peroral 
route and advantages of buccal route are lost. 
 5. Only those drugs, which are absorbed by passive diffusion, 
can be administered by this route. 
6. Eating and drinking may become restricted 
7. There is an ever present possibility of the patient swallowing 
the tablet. 
8. Over hydration may lead to the formation of slippery surface 
and structural integrity of the formulation may get disrupted 
by this swelling and hydration of the bioadhesive polymers. 
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1.5 OVERVIEW OF THE ORAL MUCOSA 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Cross section view of buccal mucosa 
 
         The oral mucosa is composed of an outermost layer of 
stratified squamous epithelium. Below this lies a basement 
membrane, a lamina propia followed by the sub mucosa as the 
innermost layer. The epithelia is similar to stratified squamous 
epithelia, found in the east of the body in that it has a mitotically 
active based cell layer, advancing through a number of 
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differentiating intermediate layers to the superficial layers, were 
cells are shed from the surface of the epithelium. The epithelium of 
the buccal mucosa is about 40-50 cell layers thick, while that of the 
sublingual epithelium contains somewhat fewer. The epithelial cells 
increase in size and become flatter as they travel from the basal 
layers to the superficial layers. 
 
The oral mucosal thickness varies depending on the site, the 
buccal mucosa measures at 500-800 µm, while the mucosal 
thickness of the head and soft palates, the floor of the mouth, the 
ventral tongue, and the gingivae measure at about 100 – 200 cm. The 
mucosae of areas subject to mechanical stress (the gingivae and hard 
palate) are keratinized similar to the epidermis. The mucosae of the 
soft palate, the sublingual and buccal regions, however, are not 
keratinized. (Harris and Robinson, 1992). Non-keratinized epithelia, 
such as the floor of the mouth and buccal epithelia do not contain 
acylceramides and only have small accounts of ceramide. 
 
They also contain small amounts of neutral but polar lipids, 
mainly cholesterol sulphate and glucosyl ceramides. These epithelia 
have been found to be consideration permeable to water than 
keratinized epithelia. (Squier et al., 1991) 
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Fig-2. General structure of the oral mucosa 
 
1.5 PERMEABILITY OF THE ORAL MUCOSA 
There is considerable difference in permeability between 
different regions of the oral cavity. In general, the permeabilities of 
the oral mucosae decrease in the order: Sublingual > buccal > 
palatal.  This rank order, however, is in accordance with the physical 
characteristics of these tissues, with the sublingual mucosae, being 
relatively thin, the buccal thicker and the palatal intermediate in 
thickness, but keratinized. 
 
a. Mechanism of Transmucosal Permeation 
 
          The majority of drugs move across epithelial membranes, 
including the oral epithelia by passive mechanisms which are 
governed primarily by the laws of diffusion. (Martindale, 2002). In 
the case of simple diffusion, two potential routes of material 
transport across the epithelium are the Paracellular and 
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Trancellular pathways. The paracellular route involves the passage 
of molecules through intercellular space, while the transcellular 
route involves transport into and across the cells. 
 
Substances with a high solubility in lipid are expected to 
traverse the oral mucosa more easily by moving along, across the 
lipid–rich plasma membranes of the epithelial cells, while water-
soluble substances and ions probably more through the intercellular 
spaces. 
 
Transmucosal permeation of polar molecules, such as peptide 
based pharmaceuticals, may be by way of paracellular route 
however, several barriers exist during the course of paracellular 
permeation. 
Fig-2a. Mechanism of Transmucosal permeation 
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b. Factors Important to Muccoadhesion  
The bioadhesive power of a polymer or of a series of polymers 
is affected by the nature of the polymer and also the nature of the 
secondary media (Duchene et al., 1988). 
 
Polymer related factors 
• Molecular Weight, 
• Concentration of active polymers, 
• Flexibility of polymer chains, 
• Spatial conformation. 
 
Environment related factors 
• pH,  
• Applied strength, 
• Initial contact time, 
• Selection of model substrate surface,  
• Swelling. 
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Fig-3.  Schematic Representation of the Absorption kinetics of buccally administered drugs 
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 c. Permeation Enhancers 
Many compounds have been cited which are used as oral 
mucosal permeation enhancers (Shojari, 1998). 
 
Table- 1. List of compounds used as oral permeation enhancers. 
 
23-laury either Cetylpyridinium chlocide 
Apotion Cetyl trimethylammonium bromide 
Azone Lysophosphatidylcholine 
Benzalkonium chloride Methyloleate 
Cyclodentrin Oleic acid 
Dentran sulphate Phosphatdyl choline 
Lauic acid Poly oxyethylene 
Propylene glycol Sodium EDTA 
Menthol Sodium glycocholate 
Methoxy  salicylate Sodium glycodeoxy cholate 
Polysorbate 80 Sodium tauryl sulphate 
Sodium salicylate Sodium taurodexycholate 
 
 
d.  Muccoadhesive Polymers 
Mucoadhesive polymers can be differentiated based on their 
adhesive performance. 
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Table 2. Mucoadhesive polymers classified according to their 
adhesive performance 
 
Excellent   
biohesives 
Fair  
performing 
polymers 
Poor agents 
Carboxymethyl 
cellulose Gum Karaya Pectis 
Carbopol 934 Gelatin Polyvinyl pyrrolidone 
Polycarbophil Guar gum Polyethylene glycol 
Tragacanth  Psyllium 
Poly acrylicacid  Amberlite -  200 resin 
Sodium alginate   
Hydroxyethyl 
cellulose   
 
1.6 EXPERIMENTAL METHODOLOGY FOR BUCCAL 
PERMEATION STUDIES                                                                                             
Before a buccal drug delivery system can be formulated, 
buccal absorption/ permeation studies must be conducted to 
determine the feasibility of their route of administration, for the 
candidate drug. These studies involve methods that could examine in 
vitro/in vivo buccal permeation profile and absorption kinetics of the 
drug. (Shojari, 1998). 
 
IN VITRO METHODS 
For the in vitro studies, animals are sacrificed immediately 
before the start of an experiment. Buccal mucosa with underlying 
connective tissue is surgically removed from the oral cavity, the 
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connective tissue is then carefully removed and the buccal mucosal 
membrane is isolated. The membranes are then placed and stored in 
ice-cold (4ºC) buffers until mounted between side-by-side diffusion 
cells for the in vitro permeation experiments. 
 
Dowfy et al, studied tissue viability by using ATP levels in 
rabbit buccal mucosae using ATP levels as an indicator for tissue 
viability is not necessarily an accurate measure however. Dowfy et 
al, reported a 50% drop in the tissue ATP concentration during the 
initial 6h of the experiment without a corresponding drop in tissue 
permeability. 
 
If the drug permeability does not change during the time 
course of the study under the specific experimental conditions of pH 
and temperature, then the tissue is considered viable. 
 
IN VIVO METHODS 
Using this method, the kinetics of drug absorption was 
measured. The methodology involves the swirling of a 25 ml sample 
of the test solution for up to 15 minutes by human volunteers 
followed by the expulsion of the solution. The amount of drug 
remaining in the expelled volume is then determined in order to 
assess the amount of drug absorbed. The drawbacks of this method 
include salivary dilution of the drug, accidental swallowing of a 
portion of a sample solution, and the inability to localize the drug 
solution, within a specific site (buccal, sublingual or gingival) of the 
oral cavity. 
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A feasible approach to achieve absorption site localization is 
to retain the drug on the buccal mucosa using a bioadhesive system. 
Pharmacokinetic parameters such as bioavailability can then be 
calculated from the plasma concentration vs. time profile. 
 
EXPERIMENTAL ANIMAL SPECIES 
               For in vivo investigations, many researches have used small 
animals including rats and hamsters for permeability studies. The rat 
has a buccal mucosa, with a very thick keratinized surface layer. The 
rabbit is the only lab rodent that has non-keratinized mucosal lining 
similar to human tissue has been extensively utilized in experimental 
studies. The oral mucosa of larger experimental animals that has 
been used for permeability and drug delivery studies include 
monkeys, dogs and pigs. 
 
1.8 EVALUATION OF NICORANDIL-BUCCAL TABLETS 
 
1. Weight variation test 
To study weight variation, 20 tablets of each formulation were 
weighed using an electronic balance, and the test was performed 
according to the official method as in USP. The weight variation 
allowed as per USP limit is 7.5%. The weights of individual tablets 
were within the USP limits. 
 
2. Drug content assay 
 
The prepared buccal tablets containing Nicorandil was tested 
for drug content uniformity as per specifications of IP 1996. Five 
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tablets were weighed individually, and the drug was extracted in 
water. The drug content was determined as described. An accurately 
weighed amount of powdered nicorandil granules (100 mg) was 
extracted with water and the solution was filtered through 0.45-µ 
membrane (New Delhi, India). The absorbance was measured at 262 
nm after suitable dilution. 
 
3. Thickness and diameter 
 
Uniform compression force and volume of die fill leads to 
uniform thickness. From each batch, 3 buccal tablets were taken and 
checked with a electronic thick-ness gauge (Mitutoyo, New Delhi, 
India). Similarly, three tablets were taken and checked for diameter 
using vernier. 
 
4. Hardness  
 
For each formulation, the hardness of 3 tablets were 
determined using the Monsanto hardness tester (Cad-mach, 
Ahmedabad, India), and the average was calculated. 
 
5. Friability 
For each formulation, the friability of 10 tablets were 
determined using the Roche friabilator (Camp-bell Electronics, 
Mumbai, India), respectively.  
 
    % Friability = Loss of weight x 100 
                                Initial weight 
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6. In-vitro drug release studies  
The in-vitro dissolution studies were carried out using USP 
apparatus type II (Tab-Machines, Mumbai, India) at 75 rpm. The 
dissolution medium consisted for the phosphate buffer pH 6.8 (250 
ml), maintained at 37°C ± 0.5°C. The formulated tablets containing 
Nicorandil equivalent to 3mg and 5mg were taken and kept in the 
dissolution medium and the paddle type stirrer was adjusted to 75 
rpm. 5ml aliquot dissolution media was withdrawn at intervals and 
volume withdrawn was replaced with fresh quantity of dissolution 
media. The drug release at different time intervals (1h, 2h, 3h, 4h, 
5h, 6h, 7h, and 8h) was measured by diode array UV-visible 
spectrophotometer at 262 nm. 
 
The percentage of Nicorandil dissolved at various time 
intervals was calculated and plotted against time. 
 
7. FT-IR compatibility studies 
 Weighed amount of the drug (3mg) was mixed thoroughly 
with 100mg of potassium bromide (dried at 40° -50° C) which was 
then compressed under 10 ton pressure in a hydraulic press to form a 
pellet which was then scanned from 4000 - 400-1cm using FT-IR 410 
PC spectrophotometer. The same procedure was repeated for 
polymers and formulations. The IR spectrum of nicorandil was 
compared with the IR spectrum of formulation.  
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8. Dissolution kinetics of drug release  
             The drug release data of nicorandil  were fitted to models 
representing Zero order (cumulative amount of drug released vs 
time), First order (log cumulative percentage of drug remaining vs 
time), Higuchi’s (cumulative percentage of drug released vs square 
root of time), and Korsmeyer’s equation (log cumulative percentage 
of drug released vs log time) kinetics to know the release 
mechanisms. The data were processed for regression analysis using 
MS-EXCEL statistical functions. These data indicated that the drug 
release followed the diffusion controlled model as described by 
Higuchi’s square root of time equation. 
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2. REVIEW OF LITERATURE 
 
2.1 Ashwin et al., (2002) studied the development and in-vivo 
evaluation of buccal tablets prepared using danazol-sulfobutyl ether 
7 β– cyclodextrin (SB & 7) complexes. They developed a 
muccoadhesive controlled release formulation of danazol sulfobytyl 
ether 7 B-cyclodextrin complex with different types of polymers, 
such as polycarbophil (PC) and HPMC to evaluate the feasibility of 
improving the bioavailability of danazol via the buccal route. 
Increased mucoadhesion was observed for PC containing tablets 
compared with HPMC tablets. As the concentration of the polymer 
increased, drug release decreased and PC containing, tablets gave 
slower release compared to HPMC tablets. 
 
2.2 Paulo et al., (2002) studied on development of buccal 
formulations based on chitosan microspheres containing 
chlorhexidine diacetate. The micro particles were prepared by spray-
drying technique, their morphological characteristics were studied by 
SEM and in vitro release behavior was investigated in pH 7.0 USP 
buffer. 
 
2.3  Shein et al., (2000) studied the enhanced bioavailability by 
buccal administration of triamicinolone acetonide from the 
bioadhesive gels in rabbits. The pharmacokinetics and bioavailability 
of triancinolone acetonide were determined to investigate buccal 
absorption from the mucoadhesive gels in rabbits. The entrancing 
affects of sodium deoxycholate as an enhancer on the buccal 
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absorption of triamcinolone acetonide from the mucoadhesion gels 
was evaluated in rabbits. Buccal administration of tramcinolone 
accetonide gels containing sodium deoxycholoate as an enhancer to 
rabbits showed a relatively constant, sustained blood concentration 
with minimal fluctuations. 
 
2.4 Wong et al., (1999) formulated and evaluated the controlled 
release buccal patches of Eudragit ME4OD, various bioadhesive 
polymers, namely HPMC, SCMC and carbopol of different grades, 
were incorporated into the patches, to modify their bioadhesive 
properties as well as the rate of drug release using metoprolol 
tartarate as model drug. The incorporation of hydrophilic polymers 
was found to affect the drug release as well as the rate of drug 
release using metoprolol tartarate as model drug. The incorporation 
of hydrophilic polymers was found to affect the drug release as well 
as enhance the bioadhesion. Although high viscosity can enhance the 
bioadhesions of the patches, they also tend to cause non-
homogenous distribution of polymers and drug resulting in non-
predictable deep release rates. 
 
2.5 Michel et al., (1987) carried out preliminary studies of oral 
mucosal delivery of peptide deeps. Comparison of plasma levels 
from buccal delivery verses i. v. infusion concluded that the buccal 
route has substantial potential for administration of peptides. 
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2.6 Hemant et al., (1999) carried out study to evaluate the gum 
Hakea as a sustained released and muccoadhesive component in 
buccal tablets following their application to the buccal mucosa of 
rabbits. Results concluded that the gum Hakea may not only used to 
sustain the release of chlorpheniramine maleate from buccal tablets 
but also demonstrate that the tablets are sufficient mucoadhesive for 
clinical application. 
 
 2.7  Hessel et al., (1989) carried cut comparison b/w bioavailability 
of prochlorperazine by IM, peroral and buccal routes. Final result 
concluded that elimination half-life was the least, with the buccal 
route and steady state plasma levels could be achieved using only 
60% of the oral dose on buccal administration. 
 
2.8 Sathish and Vincent, (1986) carried out study with respect to 
enkephelin hydrolysis in homogenates of various absorptive 
mucosae of the albino rabbit in order to assess similarities in rates 
and involvement of amino peptidases. Results concluded that the 
same enzymatic barrier to en kephalin absorption possibility exists in 
both the oral and non-oral mucosae. 
 
2.9 Aungst et al., (1988) (carried out study with respect to 
comparison of the effects of various transmucosal absorption 
promoters on buccal insulin delivery. Results concluded that non-
ionic surfactants wherein the hydrophobic and hydrophilic portions 
are joined through ether linkage can be effective buccal absorption 
promoters but that those with other bonds are not. 
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2.10 Laila et al., (1992) carried out study with respect to buccal 
absorption of Ketobemide and various ester prodrugs in the rat. 
Results concluded that all prodrugs show an increased extend of 
absorption relative to that of the parent drug. 
 
2.11 Patel et al., (2006) prepared buccal adhesive patches containing 
20 mg of propanolol hydrochloride using solvent casting method. 
Patches were prepared at different ratios of PVP K-30 which 
generally enhances the releasing rate and evaluated for various 
physicochemical characteristics such as weight variation, drug 
content conformity, folding endurance, surface pH, mucoadhesive 
strength, ex-vivo residence time, in vitro drug release and in vitro 
buccal permeation study. Patches exhibited sustained release over a 
period of 7 hours. The mechanism of drug release was found to be 
non-ficikian diffusion. 
 
2.12 Nina et al., (2005) studied the enhanced bioavailability by 
buccal adminstration of PACAP (Pituitary adenylate cyclase – 
activating polypeptide). A strong mucoadhesive chetosaric-
thiogloycolic acid (TG A) conjugate in combination with reduced 
glutathione (GSH) on permeation of PACAP across buccal mucosa 
were used.  Release studies indicated that a controlled release can be 
provided from tablets consisting of chitosan – TGA at a pH of 5, 
whereas more than twice as much was released from chitosan TGA 
tablets pH4. Combination of permeation enhancing properties, 
controlled drug release and muccoadhesion character, chitosan – 
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TGA conjugates represent a promising tool for buccal administration 
of PACAP. 
 
2.13 Reinhold et al., (1989) developed and evaluated buccoadhesive 
patches, consisting of two ply laminates of an impermeable backing 
layer and a hydrocolloid polymer layer containing the drug. Patches 
were prepared by a casting procedure using various aqueous 
solutions of drugs and hydrocolloid polymers and subsequent drying. 
The polymers used were hydroxyl ethyl cellulose, hydroxyl propyl 
cellulose, polyvinyl pyrollidone and polyvinyl alcohol. Adhesion to 
the mucosal surface was established by interactions of the swollen 
polymer and buccal mucosal layer. A wide range of controlled drug 
release rate can be achieved by polymer dissolution kinetics. 
 
2.14 Smart et al., (1991) developed an in vitro method for 
assessment of the adhesive force between a disc of test material and 
a model mucus membrane and the method has reproducibility. It was 
concluded that only a small force is required to retain a dosage form 
within the buccal cavity. Carbopol 934P and EX55 (Polycarbophil) 
formed the most stable adhesive bond which remained intact for 8 
hours. 
 
2.15 Carmen et al., (1998) prepared buccal bilayered device 
containing mucoadhesive and drug free backing layer by two 
different methods namely by a casting/solvent evaporation technique 
and bilayered tablets were obtained by direct compression. The 
mucoadhesive layer composed of a mixture of drug ( Nifedipine or 
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Propanolol Hydrochloride) and chitosan with or without  an anionic 
crosslinking polymer (polycarbophil, sodium alginate, gellan gum) 
and backing layer made of ethylcellulose. Bilaminated film showed 
sustained release in pH 6.4 phosphate buffer. Uncrosslinked chitosan 
containing device absorbed large quantity of water gel and eroded 
allowing drug release. Crosslinked chitosan with carbophil displayed 
controlled release and adequate adhesivity. 
 
2.16 Han-Gon et al., (2000) developed an omeprazole buccal 
adhesive tablet. A mixture of sodium alginate and HPMC was 
selected as the bioadhesive additive for the omeprazole tablet. The 
bioadhesive polymers alone had the bioadhesive force suitable for 
buccal adhesive tablets, but the suitability in human saliva was not 
satisfied. So magnesium oxide is used as an alkali stabilizer, due to 
its waterproofing effects. It was concluded that two tablets composed 
of (omeprazole/ sodium alginate/HPMC/Magnesium oxide 
[20/24/6/50.mg/tab] and [20/30/0/50 mg/tab] could be attached to 
human cheeks without collapse and could be stabilized in human 
saliva for atleast  4 hours.   
 
2.17 Juan Manuel et al., (2002) designed a two layered 
mucoadhesive tablet containing nystatin for the treatment of oral 
candidosis. Lactose CD, Carbomer (CR), hydroxyl propyl methyl 
cellulose (HPMC) was used as excipients. Properties such as in vitro 
mucoadhesion, water uptake, front movements and drug release were 
evaluated. The mixture CB: HPMC, 9:1 showed good in vitro 
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mucoadhesion. A swelling –diffusion process modulates the release 
of nystatin from this layer. A non-fickian kinetic was observed. 
 
2.18 Varshosaz and Dehgahan, (2002) prepared buccoadhesive 
controlled release tablets. The tablet contained 30mg of nifedipine 
and various amount of carboxymethylcellulose (CMC), carbomer 
(CP), polyvinylpyrolidone (PVP), polyvinyl alcohol (PVA), hydroxy 
propyl methyl cellulose (HPMC). The highest adhesion force was 
observed in 8:2 ratio of CP: CMC and 35%CP adhered for over 8 
hours to the upper gum of 6 healthy human volunteer and a good 
correlation (r2=0.989) was observed between drug released in vitro 
and in vivo. 
 
2.19 Desai and Kumar, (2004) evaluated the mechanism of 
absorption of propanolol hydrochloride through porcine buccal 
mucosa. The tablet was prepared in a specially designed and 
fabricated punch. HPMC and Carbopol 934P were used as polymers. 
The tablets were evaluated for weight uniformity, friability, 
hardness, swelling, mucoadhesive strength, in vitro drug release, 
stability and in vitro acceptability. The order of release was by non –
fickian diffusion and first order kinetics. In vivo studies indicated 
that tablet was comfortable in oral cavity, not heavy and did not 
cause any side effects. 
 
2.20  Ikinci et al., (2004) developed a bioadhesive buccal tablet for 
delivery of nicotine. The bioadhesive polymers, carbomer (Carbopol 
974P NF) and alginic acid sodium salt (NaAlg) were used in 
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combination with HPMC at different ratios. Magnesium carbonate 
was added as a pH increasing agent, in vitro studies and bioadhesion 
studies were carried out and found that they released nicotine for 8 
hours period and remained intact except for the formulation 
containing CP: HPMC at 20:80 ratio. 
 
2.21  Kashappa et al., (2004) prepared and evaluated a novel buccal 
adhesive system (NABS) containing propanolol hydrochloride using 
hydroxy propyl methyl cellulose (HPMC), Carbopol 934P. A special 
punch was fabricated and used while preparing an NBAS.NBAS was 
evaluated by weight uniformity, thickness, hardness, friability, 
swelling, mucoadhesive strength, in vitro drug release, and in vivo 
human acceptability studies. It was concluded that NBAS is 
superior, novel system that overcomes the draw back associated with 
the conventional buccal adhesive tablet. 
 
2.22  Park and Munday, (2004) evaluated some naturally occurring 
bioincompatible materials such as xanthan gum, karaya gum, guar  
gum and glycol chitosan as mucoadhesive controlled release 
excipients for buccal drug delivery. Tablets were prepared in a range 
of 0-50% of gum, in which glycol, chitosan produced the strongest 
adhesion, but concentration greater than 50% w/w are required to 
produce a non-erodible matrix that can release for over 4 hours and 
swelling properties of tablets were found to know the ability of the 
material to produce sustained release. 
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 2.23 Vijayaraghavan and Ravi, (2004) studied the effect of 
formulation variables  on the buccal absorption of a low dose of 
nifedipine (ND) which was done firstly to determine the influence of 
the incorporation of natural flax seed polymer (FSP) on 
bioavailability of ND after peroral administration  with buccal 
administration. Formulation contains 10mg of ND and 10, 20, 30, 
40mg of FSP as well as peroral administration with buccal of a 
formulation of 10mg of ND alone. In vitro study carried out in pH 
(6.8) phosphate buffer and bioavailability studies were carried out in 
9 male healthy volunteer. A HPLC method was used to determine 
the plasma concentration. Bioavailability was improved with 10mg 
and 30mg of FSP than ND alone. The inclusion of flax seed polymer 
into the formulation resulted in increase in bioavailability due to 
increase in adhesion and faster release characteristic of the polymer. 
 
2.24  Jamakandi et al., (2009) investigation aimed at evaluating the 
possibility of using different polymeric grades of hydroxypropyl 
methyl cellulose for the development of transdermal drug delivery 
systems of nicorandil, an anti-anginal drug. Prepared matrix-type 
patches were evaluated their physiochemical characterization 
followed by in vitro evaluation. Selected formulations were 
subjected for their ex vivo studies on porcine ear skin. 
 
2.25 Bupinder et al., (2006) designed oral controlled release 
mucoadhesive compressed hydrophilic matrices of atenolol. Tablets 
were prepared by direct compression and evaluated for bioadhesive 
strength and in vitro dissolution parameters. Carbopol 934P and 
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sodium carboxy methyl cellulose were taken as the independent 
variables. Compressed matrices exhibited non-Fickian drug release 
kinetics approaching zero order. 
            
2.26   Shaila Lewis et al., (2006) formulated mucoadhesive tablets 
for buccal administration of nicotine. Three types of tablets were 
developed each containing two mucoadhesive components (HPMC 
and Sodium Alginate), (HPMC and Carbopol), (Chitosan and 
Sodium Alginate). For each of these types, batches were produced 
changing the quantity of polymers resulting in nine different 
formulations. The tablets were evaluated for release pattern and 
mucoadhesive performance. Pharmacokinetic studies were 
conducted in smokers. A peak plasma concentration of 16.78±2.27 
mg was obtained in two hours, which suggests potential clinical 
utility in Nicotine replacement therapy.   
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3. SCOPE AND OBJECTIVE OF THE WORK 
 
The scope of any formulation primarily focuses on safety and 
efficacy of the drug delivery system. Now the focus has been slightly 
moved to the patient’s convenience and acceptance, where still the 
safety and efficacy remain integrated with design. Recent research 
efforts through out the world have resulted in significant 
development of novel drug delivery systems. 
 
In recent years, there has been increasing interest in the use of 
bioadhesive polymers to control the delivery of biologically active 
agents systemically or locally. These bioadhesive systems are useful 
for the administrative of drugs, which are susceptible to extensive 
gastro intestinal degradation and first pass metabolism. Bucolic 
adhesive system appears to be attractive because it avoids significant 
limitations of traditional routes of drug administration such as poor 
absorption, enzymatic degradation and first pass metabolism. 
 
Buccal delivery necessitates the use of mucoadhesive polymer 
as their dosage forms should ideally adhere to the mucosa and 
withstands salivation, tongue movement and swallowing for a 
significant period of time. 
 
The objective of the present study was to formulate a suitable 
drug delivery system through the buccal mode, for the long term 
treatment and prevention of angina pectoris. 
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Hypertension and angina pectoris, the most common 
cardiovascular diseases, require constant monitoring. The first 
therapeutic drug shown to possess an ability to hyperpolarize smooth 
muscle cell membranes is nicorandil, a potent coronary vasodilator 
(Frydman et al., 1989). Although nicorandil is one of the emerging 
molecules is the case of hypertension and angina, successful 
treatment means maintenance of blood pressure at a normal 
physiological level, for which a constant and uniform supply of drug 
is desired (Leonetti et al, 1989, Camm et al, 1989). 
 
          Buccal delivery of drugs provide an attractive alternative to 
the oral route of drug administration, particularly in overcoming 
deficiencies associated with the latter mode of administration 
problems such as high first pass metabolism, drug degradation in 
harsh gastrointestinal environment can be circumvented by 
administering a drug via buccal route. 
 
Moreover, buccal drug delivery offers a safer method of drug 
utilization, since drug absorption can be promptly terminated in case 
of toxicity by removing the dosage form the buccal cavity (Wong FC 
et al., 1999). It is also possible to administer the drug to patients, 
who cannot be dosed orally to prevent accidental swallowing. 
 
Buccal releases of nicorandil is enabled so that it can be 
retained in the oral cavity for desired duration and localize the 
dosage form in a specific region and control the release rate of drug. 
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4. PLAN OF THE WORK 
 
           The work entitled, “DEVELOPMENT AND 
EVALUATION OF A BUCCAL DRUG DELIVERY SYSTEM 
FOR THE ANTI-ANGINAL DRUG-NICORANDIL” was 
planned in an aim to achieve the objective described earlier. The 
work was carried out for a period of 9 months (May 2009 to January 
2010) which was divided into three phases like 
 
Phase I (May - June 2009) 
1. Literature survey. 
2. Identification of the objective for the current study. 
3. Optimization of the methodology 
 
Phase II (July - December 2009) 
1. Preparation of standard graph for the drug. 
2. Preparation of nicorandil buccal tablets by direct compression 
method. 
 
• Method 1- Buccal tablet with coated backing layer of 
ethyl cellulose. 
• Method 2- Bilayered buccal tablet with backing layer of 
ethyl cellulose. 
 
 
 
 
Chapter IV          Plan of the Work
     
 
- 33 - 
 
3. Evaluation of the physical characteristics. 
3.1. Compatibility study using Infra Red (IR) spectroscopy. 
3.2. Tablet assessed with respect to physical parameters such as        
friability studies, FT-IR Studies, Swelling studies and        
swelling Index, tablet thickness, weight variation test,        
hardness and n-vitro drug release. 
4. Drug content analysis. 
5. Dissolution Kinetics of drug. 
    
Phase III (January 2010) 
1. Compilation and preparation of reports. 
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5. MATERIALS AND EQUIPMENTS 
 
Table: 3 Materials used 
 
Name of the materials Name of the company 
Nicorandil (gift sample) Sai Mirra Innopharm Pvt Ltd, Chennai. 
Carbopol 934 Hi Media Laboratories Ltd, Mumbai. 
Polyvinyl alcohol S.D.Fine Chemicals Ltd, Mumbai 
Polyvinyl pyrollidone S.D.Fine Chemicals Ltd, Mumbai 
Ethyl Cellulose Loba Chemie Pvt Ltd, Mumbai 
Magnesium Stearate Loba Chemie Pvt Ltd, Mumbai 
Mannitol S.D.Fine Chemicals Ltd, Mumbai 
β-Cyclodextrin S.D. Fine Chemicals Ltd, Mumbai 
Distilled Water Industrial  Scientific  Enterprises, Namakkal. 
 
Table: 4. Equipments used 
 
Name of equipment Name of  the company 
UV / Vis 
Spectrophotometer JASCO V-530. 
Dissolution apparatus Electrolab TDT-08L. Chennai. 
Digital balance Denver instruments 
FT-IR Spectrophotometer Jasco-FT-IR 8201 PC 
Electronic Digital 
Micrometer Aerospace Pvt. Ltd 
Monsanto Hardness Tester Cad-Mach, Ahmedabad, India 
pH tester 1 (water proof) Oakton instruments. 
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6. DRUG PROFILE 
Nicorandil 
                 Nicorandil is one of the emerging molecules in the case of 
hypertension and angina and behaves as a potent coronary 
vasodilator. 
 
Chemical name 
                2-[(pyridin-3-ylcarbonyl) amino] ethyl nitrate 
 
Empirical formula 
                C8H9N3O4 
 
Chemical Structure: 
 
Fig : 4. Structure of  Nicorandil 
 
Mol. mass 
       211.175 g/mol  
 
Characteristics 
       White or almost white powder. Freely soluble in water, acetone 
and chloroform. 
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6.1 PHARMACOLOGY 
 
Nicorandil, a drug approved for the treatment of ischemic 
heart disease, has dual properties. The intrinsic mechanism of the 
drug (selective activation of K+ATPchannels at the sarcolemmal and 
mitochondrial level) allows coronary and peripheral vasodilatation 
with subsequent reduction of preload and afterload. Secondly, 
because of the role K+ATPchannels in ischemic preconditioning, 
nicorandil have been attributed cardio protective effects. 
 
Nicorandil acts by relaxing the smooth muscle of the blood 
vessels, especially those of the venous system. It does this through 
two methods. Firstly, by activating potassium channels, and 
secondly by donating nitric oxide to activate the enzyme guanylate 
cyclase. Guanylate cyclase causes activation of GMP leading to both 
arterial and venous vasodilatation. As it is selective for vascular 
potassium channels, it has no significant action on cardiac 
contractility and conduction. 
 
Although it can dilate the coronary vessels of a healthy 
individual, its effects on the coronary vessels of someone with 
ischaemic heart disease will be little as they will already be 
completely dilated. As it couples arterial dilation along with 
venodilation, it reduces the preload and the afterload of the heart. 
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6.2 INDICATIONS 
 Angina Pectoris, 
 Hypertension, 
 Congestive heart failure 
 
6.3 PHARMACOKINETICS  
 Onset of Action -30min - 60 min  
 Cmax -90 min 
 Protein binding- 20-25% 
 Metabolism –denitration of the molecule into the nicotinamide 
pathway, 
 Elimination Half-life-2 hours 
 
6.4 SIDE EFFECTS 
          Common side effects include flushing, palpitation, weakness, 
headache, mouth ulcers, nausea and vomiting. More recently peri-
anal, ileal and peri-stomal ulceration has been reported as a side 
effect. Anal ulceration is now included in the British National 
Formulary as a reported side effect. 
 
6.5 STABILITY 
          Store below 25°C. Protect from light and moisture.  
 
6.6 CONTRAINDICATIONS AND PRECAUTIONS  
Contraindications  
            Nicorandil is contraindicated in patients with cardiogenic 
shock, left ventricular failure with low filling pressures and in 
hypotension. It is also contraindicated in patients who have 
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demonstrated an idiosyncratic response or hypersensitivity to 
nicorandil. Due to the risk of severe hypotension, the concomitant 
use of Ikorel and phosphodiesterase 5 inhibitors (e.g. sildenafil, 
tadalafil, vardenafil) is contraindicated. 
 
Pregnancy implications 
          Animal studies have not shown drug related teratogenic or 
primary embryo toxic effects on animal fetuses; however 
comparative studies have not been done in humans. Use only when 
benefit outweighs potential risk in a pregnant woman. 
 
6.7 DRUG INTERACTIONS   
Drug –drug combinations  
No pharmacological or pharmacokinetic interactions have 
been observed in humans or animals with beta-blockers, digoxin, 
rifampicin, cimetidine, acenocoumarol, a calcium antagonist or a 
combination of digoxin and furosemide. Nevertheless, there is the 
possibility that nicorandil may potentiate the hypotensive effects of 
other vasodilators, tricyclic antidepressants or alcohol.  
 
Gastrointestinal perforations in the context of concomitant use 
of nicorandil and corticosteroids have been reported. Caution is 
advised when concomitant use is considered. 
 
Chapter VI        Drug Profile
      
 
- 39 - 
 
6.8 MARKETED FORMULATION 
 
Table: 5 List of some marketed formulations of Nicorandil 
 
Trade name Tablet Injection Manufacturer 
AV-COR 5mg,10mg  GRANDIX 
CORFLO 5mg,10mg  WOCKHARDT 
KORANDIL 5mg,10mg  SUN 
NIKORAN 5mg,10mg 2mg, 4mg vials TORRENT 
ZYNICOR 5mg  ZYDUS CADILA 
 
6.9 ADVERSE DRUG REACTIONS  
 
The following undesirable effects have been reported from the 
original clinical trials for the prevention and long-term treatment of 
chronic stable angina and post-marketing experience.  Very common 
(>1/10); common (>1/100, <1/10); uncommon (>1/1,000, <1/100); 
rare (>1/10,000, <1/1,000); very rare (<1/10,000), including isolated 
reports.  
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Table:  6    List of some Reported Adverse Drug Reactions 
 
SOC FREQUENCY ADR 
Immune system 
disorders 
Very rare Angioedema 
Nervous system 
disorders 
Very common 
 
Headache, usually of a 
transitory nature, especially 
when treatment is initiated 
 Common Dizziness 
Cardiac disorders Uncommon An increase in heart rate at 
high doses 
Vascular disorders Common Cutaneous vasodilation with 
flushing 
 
 
Uncommon Hypotension at high 
therapeutic doses 
Gastrointestinal 
disorders 
Common Nausea and vomiting 
 
 
Rare Persistent aphtosis or mouth 
ulcers which were 
occasionally severe 
Hepato-biliary 
disorders 
Rare Hepatic function 
abnormalities 
Skin and 
subcutaneous tissue 
disorders 
Rare Various types of rash 
Musculoskeletal & 
connective tissue 
disorders 
Rare Myalgia 
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7. POLYMER PROFILE 
 
7.1 CARBOPOL-934  
Chemical name       :  Acrylic acid copolymer 
IUPAC name            :  prop-2-enoic acid 
Chemical formula   :  C3H4O2 
Appearance             :  White, fluffy powder  
Odor                         :  Slightly acetic 
7.1.1 Characteristics and application:     
Maintain stability of the o/w type emulsion system, 
Applicable to various gel and cream, emulsion. Carbopol 934 is a 
superior suspending agent, which permits uniform and permanent 
dispersion of water-insoluble test compounds. Carbopol polymers 
have an average equivalent weight of 76 per carboxyl group. The 
general structure can be illustrated with fig.4 &5. 
 
Fig : 4   Chemical Structure of Carbopol 
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Fig :  5. General structure of carbopol polymers 
 
 
7.1.2 Physical properties 
 
         Carbopol 934 P is cross-linked with allyl sucrose and is 
polymerized in solvent benzene. The three dimensional nature of 
these polymers confers some unique characteristics, such as 
biological inertness, not found in similar linear polymers. The 
Carbopol resins are hydrophilic substances that are not soluble in 
water. Rather, these polymers swell when dispersed in water forming 
a colloidal, mucilage-like dispersion.  
 
          Carbopol polymers are bearing very good water sorption 
property. They swell in water up to 1000 times their original volume 
and 10 times their original diameter to form a gel when exposed to a 
pH environment above 4.0 to 6.0. Because the pKa of these 
polymers is 6.0 to 6.5, the carboxylate moiety on the polymer 
backbone ionizes, resulting in repulsion between the native charges, 
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which adds to the swelling of the polymer. The glass transition 
temperature of Carbopol polymers is 105°C (221°F) in powder form. 
However, glass transition temperature decreases significantly as the 
polymer comes into contact of water. The polymer chains start 
gyrating and radius of gyration becomes increasingly larger. 
Macroscopically, this phenomenon manifests itself as swelling. 
  
Appearance__ Fluffy, white, mildly acidic polymer 
 
7.1.3 Rheological properties 
 
          While the relationships between structure and properties have 
been of interest both academically and in industry. Different grades 
of Carbopol polymers exhibit different rheological properties, a 
reflection of the particle size, molecular weight between crosslinks 
(Mc), distributions of the Mc, and the fraction of the total units, 
which occur as terminal, i.e. free chain ends.  
 
         The molecular weights between adjacent crosslinks (Mc) are 
approximately inversely proportional to the crosslinker density. 
These may be calculated from the functionality of the crosslinking 
monomer, the relative ratio of acrylic acid to crosslinking monomer,  
and the efficiency of the crosslinking reaction, assuming negligible 
chain ends. Alternatively, the molecular weight can be qualitatively 
compared to the rheological properties of a swollen gel and/or from 
the equilibrium-swelling ratio. In simple terms, low viscosity, low 
rigidity polymers, such as Carbopol 941 and Carbopol 971P, have a 
higher Mc. Conversely, they have lower crosslinker densities. The 
higher the crosslinker level, the lower the equilibrium swelling ratio.   
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7.1.4 Applications of carbopol polymers: 
The readily water-swellable Carbopol polymers are used in a 
diverse range of pharmaceutical applications to provide:  
 Controlled release in tablets. 
 Bioadhesion in buccal, ophthalmic, intestinal, nasal, vaginal 
and rectal applications. 
 Thickening at very low concentrations to produce a wide 
range of viscosities and flow properties in topical, lotions, 
creams and gels, oral suspensions and transdermal gel 
reservoirs. 
 Permanent suspensions of insoluble ingredients in oral 
suspensions     and topicals. 
 Emulsifying topical oil-in-water systems permanently, even at 
elevated temperatures, with essentially no need for irritating 
surfactants.  
Several properties of Carbopol make it potentially valuable as 
a pharmaceutical excipient in numerous applications such as:  
 
7.1.5 Controlled release & solid dosage forms   
 
            Carbopol is being used in the controlled release solid dosage 
formulations since last four decades. Tablet formulations using 
Carbopol polymers have demonstrated zero-order and near zero-
order release kinetics. These polymers are effective at low 
concentrations (less than 10%). Still they show extremely rapid and 
efficient swelling characteristics in both simulated gastric fluid 
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(SGF) and simulated intestinal fluid (SIF). The Carbopol polymers 
produce tablets of excellent hardness and low friability. These 
polymers can be successfully formulated into a variety of different 
tablet forms, including the traditional swallowable tablets, chewable 
tablets, buccal tablets, sublingual tablets, effervescent tablets, and 
suppositories; providing controlled-release properties as well as 
good binding characteristics. Carbomers show larger dissolution 
times at lower concentrations of the polymer.  
 
             Because of these factors Carbopol polymers have greater 
extent in formulating dosage forms. Because Carbopol polymers 
swell rapidly in water quantities and absorb great, to avoid the use of 
flammable solvents, roller compaction is being used as the method to 
prepare a new form of Carbopol polymer71 GNF. Carbopol polymer 
71G NF is a useful and versatile controlled-release additive for tablet 
formulations in direct compression.  
 
Drug dissolution mechanism from carbopol polymers  
              In the dry state, the drug is trapped in a glassy core. As the 
external surface of the tablet is hydrated, it also forms a gelatinous 
layer upon hydration; however, this gel layer is significantly 
different structurally from the traditional matrix tablet. The 
hydrogels are not entangled chains of polymer, but discrete 
microgels made up of many polymer particles, in which the drug is 
dispersed. The crosslink network enables the entrapment of drugs in 
the hydrogel domains. Since these hydrogels are not water soluble, 
they do not dissolve, and erosion in the manner of linear polymers 
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does not occur. Rather, when the hydrogel is fully hydrated, osmotic 
pressure from within works to break up the structure, essentially by 
sloughing off discrete pieces of the hydrogel. It is postulated that as 
the concentration of the drug becomes high within the gel matrix and 
its thermodynamic activity or chemical potential increases, the gel 
layer around the tablet core actually acts almost like a rate-
controlling membrane, resulting in linear release of the drug. 
Because of this structure, drug dissolution rates are affected by 
subtle differences in rates of hydration and swelling of the individual 
polymer hydrogels, which are dependent on the molecular structure 
of the polymers, including crosslink density, chain entanglement, 
and crystalline of the polymer matrix. The magnitude and rate of 
swelling is also dependent on the pH of the dissolution medium. The 
channels which form between the polymer hydrogels are influenced 
by the concentration of the polymer, as well as the degree of 
swelling. Increasing the amount of polymer will decrease the size of 
the channels, as does an increase in swelling degree. All of these 
factors must be taken into account to describe the mechanism for 
release control in tablets formulated with Carbopol polymers.  
 
Benefits in solid dosage application  
 
• Efficient controlled release agents for matrix tablets.  
• Improve bioavailability of certain drugs  
• Efficient binders in dry as well as wet granulation processes.  
• Only granular polymer (Carbopol 71G NF) available for direct 
compression formulation.  
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7.1.6 Oral suspension applications  
           For many years, Carbopol polymers have been widely used in 
oral suspensions to thicken, modify flow properties, suspend 
insoluble ingredients and provide bioadhesion. The significance of 
these polymers is that they eliminate the settling problem even at 
low concentrations. As Carbopol polymers swell when hydrated and 
neutralized, they form colloidal dispersion.  
 
Carbopol 934 P has been used since mid 1960s. Carbopol 974 
P has similar rheological properties to Carbopol 934 P, as both are 
highly cross-linked polymers that produce mucilage with very short 
flow rheology. Carbopol 971 P provides very low viscosities and 
excellent yield values at low usage levels. Suspensions formed with 
Carbopol 971 P will have longer rheology. Carbopol 71 G polymers 
will give same viscosities and rheology as Carbopol 971 P, but it is 
easier to handle and disperse due to its granular nature.  
 
Benefits in oral suspension applications 
• Long Term Stability of Suspensions over a wide pH range.  
• Highly efficient at low use level.  
• Taste masking of some bitter drugs.  
• Build viscosity and yield value for “non-spill” pediatric 
formulations.  
7.1.7  Bioadhesive applications  
 
            Bioadhesion is a surface phenomena in which a material may 
be of natural or synthetic origin, adheres or stick to biological 
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surface, usually mucus membrane. The concept of bioadhesion is 
emerging as a potential application in drug delivery due to its 
applicability for bioavailability enhancement, prolongation of 
residence time for drug in GIT and better contact between drug and 
absorbing surface.  
 
Many hydrophilic polymers adhere to mucosal surfaces as 
they attract water from the mucus gel layer adherent to the epithelial 
surface. This is the simplest mechanism of adhesion and has been 
defined as “adhesion by hydration” Various kinds of adhesive force, 
e.g. hydrogen bonding between the adherent polymer and the 
substrate, i.e. mucus, are involved in mucoadhesion at the molecular 
level. Carbopol polymers have been demonstrated to create a 
tenacious bond with the mucus membrane resulting in strong 
bioadhesion. 
 
Many commercial oral and topical products available today 
and under investigation have been formulated with Carbopol 
polymers, as they provide numerous benefits in bioadhesive 
formulations.  
 
Benefits in bioadhesive applications  
 
¾ Improve bioavailability of certain drugs.  
¾ Enhance patient compliance (fewer doses are needed per day)  
¾ Lower concentrations of the active ingredients can be used.  
¾ Provide excellent adhesion forces.  
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7.1.8 Topical applications:  
 
Carbomers are very well suited to aqueous formulations of the 
topical dosage forms:  
¾ Safe & Effective : Carbopol polymers have a long history of 
safe and effective use in topical gels, creams, lotions, and 
ointments. They are also supported by extensive toxicology 
studies 
¾ Non-Sensitizing : Carbopol polymers have been shown to 
have extremely low irritancy properties and are non-
sensitizing with repeat usage.  
¾ No Effect on the biological activity of the drug:  Carbopol 
polymers provide an excellent vehicle for drug delivery. Due 
to their extremely high molecular weight, they cannot 
penetrate the skin or affect the activity of the drug.  
¾ Excellent thickening, suspending, & emulsification 
properties for topical formulations  
7.1.9 Oral care applications 
 
Carbopol polymers impart several desirable characteristics to 
toothpaste formulations like viscosity, yield value, low thixotropy 
and clarity.  
 
        Imparting viscosity at very low concentrations to thicken a 
system is a primary function of the polymers. Suspending abrasives 
and solid actives is accomplished through the build of yield value at 
low polymer concentrations. The combination of Carbopol 
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polymers’ ability to build yield value with low thixotropy provides 
for a clean, non-stringing ribbon of toothpaste. From aesthetic and 
practical perspectives this means that Carbopol toothpaste 
formulations are pumpable, leave minimal solids residue on the tube 
rim, stand up well on the brush, and can be used in clear 
formulations.  
 
Benefits in oral care applications  
 
¾ Efficient co-binders at low usage levels.  
¾ Suspending agents for non-soluble actives or excipients.  
¾ Thicken peroxide gel systems while maintaining product 
stability.  
¾ Compatible with commonly used formulation ingredients.  
The large variety of applications as well as the steadily 
increasing number of research workers engaged in studies of 
Carbopol polymers due to their unique properties, have made 
significant contributions to many types of formulations and suggest 
that the potential of Carbopol as novel and versatile polymer will be 
even more significant in future.  
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7.2 POLYVINYL ALCOHOL 
Structural formula 
 
Fig : 6  Chemical structure of PVA. 
 
7.2.1 Properties 
Polyvinyl alcohol has excellent film forming, emulsifying, and 
adhesive properties. It is also resistant to oil, grease and solvent. It is 
odorless and nontoxic. It has high tensile strength and flexibility, as 
well as high oxygen and aroma barrier properties. However these 
properties are dependent on humidity, in other words, with higher 
humidity more water is absorbed. The water, which acts as a 
plasticizer, will then reduce its tensile strength, but increase its 
elongation and tear strength. PVA is fully degradable and is a quick 
dissolver. PVA has a melting point of 230°C and 180–190°C for the 
fully hydrolysed and partially hydrolysed grades. It decomposes 
rapidly above 200°C as it can undergo pyrolysis at high 
temperatures. 
PVA is an ataxic material but exhibits crystallinity as the 
hydroxyl groups are small enough to fit into the lattice without 
disrupting it. 
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Molecular formula   :  (C2H4O) x 
Melting point            :  230°C 
Boiling point             :  228°C 
7.2.2 Uses 
Some of the uses of polyvinyl alcohol include: 
1. Adhesive and thickener material in latex paints, paper  
coatings, release liner, hairsprays, shampoos and glues.  
2. Textile sizing agent  
3. Feminine hygiene and adult incontinence products as a 
biodegradable plastic backing sheet.  
4. As a mold release because materials such as epoxy do not 
stick to it.  
5. As a water-soluble film useful for packaging.  
6. Used in eye drops and hard contact lens solution as a 
lubricant.  
7. Used in protective chemical-resistant gloves  
8. Used as a fixative for specimen collection, especially stool 
samples  
9. When doped with iodine, PVA can be used to polarize light.  
    10. As an embolization agent in medical procedures  
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7.3 P OLYVINYL PYRROLIDONE 
Polyvinylpyrrolidone (PNVP, PVP, povidone, polyvidone) 
is a water-soluble polymer made from the monomer N-
vinylpyrrolidone: 
 
 
 
Fig : 7   Chemical structure  of  PVP 
 
7.3.1 Properties 
 
PVP is soluble in water and other polar solvents. In water it 
has the useful property of Newtonian viscosity. When dry it is a light 
flaky powder, which readily absorbs up to 40% of its weight in 
atmospheric water. In solution, it has excellent wetting properties 
and readily forms films. This makes it good as a coating or an 
additive to coatings. 
 
7.3.2 Uses 
The monomer is extremely toxic to aquatic life. However, the 
polymer PVP was used as a blood plasma expander for trauma 
victims after the first half of the 20th century. 
 
It is used as a binder in many pharmaceutical tablets; it simply 
passes through the body when taken orally. PVP added to Iodine 
forms a complex (Povidone-iodine) that possesses disinfectant 
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properties. This complex is contained in various products like 
solutions, ointment, pessaries, liquid soaps and surgical scrubs.  
 
PVP binds to polar molecules exceptionally well, owing to its 
polarity. This has led to its application in coatings for photo-quality 
ink-jet papers and transparencies, as well as in inks for inkjet 
printers. 
 
PVP is also used in personal care products, such as shampoos 
and toothpastes, in paints, and adhesives that must be moistened, 
such as old-style postage stamps and envelopes. It has also been used 
in contact lens solutions and in steel-quenching solutions. PVP is the 
basis of the early formulas for hair sprays and hair gels, and still 
continues to be a component of some. 
 
As a food additive, PVP is a stabilizer and has E number 
E1201. PVPP is E1202. It is also used in the wine industry as a 
fining agent for white wine. 
 
In molecular biology, PVP can be used as a blocking agent 
during Southern blot analysis as a component of Denhardt's buffer. It 
is also  exceptionally good at adsorbing polyphenols during DNA 
purification. Polyphenols are common in many plant tissues and can 
deactivate proteins if not removed and therefore inhibit many 
downstream reactions like PCR. 
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PVP is also used in many technical applications: 
 as adhesive in glue stick and hot melts  
 as special additive for batteries, ceramics, fiberglass, inks, 
inkjet paper and in the chemical-mechanical planarization 
process  
 as emulsifier and disintegrant for solution polymerization  
 as photo resist for cathode ray tubes (CRT)  
 use in aqueous metal quenching  
 for production of membranes, such as dialysis and water 
purification filters  
 as binder and complexation agent in agro applications such 
as crop protection, seed treatment and coating  
 as a thickening agent in tooth whitening gels,  
 as an aid for increasing the solubility of drugs in liquid and 
semi-liquid dosage forms (syrups, soft gelatin capsules) 
and as an inhibitor of recrystallisation. 
  
7.3.3 Cross-linked derivatives 
A cross-linked form of PVP is also used as a disintegrant in 
pharmaceutical tablets. It is also known as cross-linked polyvinyl 
pyrrolidone, Polyvinyl Polypyrrolidone (PVPP), crospovidone, 
crospolividone. Basically, PVPP is a highly cross-linked version of 
PVP, which makes it insoluble in water but it still absorbs water and 
swells very rapidly and generate a swelling force. That is why it can 
be used a disintegrant in tablets. It is also used to bind impurities to 
remove them from solutions. It is also used as a fining to extract 
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impurities (via agglomeration followed by filtration). Using the same 
principle it is used to remove polyphenols in beer production and 
thus clear beers with stable foam are produced. PVPP can be used as 
well as a drug taken as a tablet or suspension and it absorbs 
compounds (so called Endotoxins) causing diarrhoea.  
 
Molecular formula :  (C6H9NO)n 
Molar mass               :  2.500 - 2.5000.000 g·mol−1 
Appearance               :  white to light yellow, hygroscopic,  
amorphous powder 
Density                     :  1.2 g/ cm³ 
Melting point             :  110 - 180 °C (glass temperature) 
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7.4 ETHYL CELLULOSE 
 
Chemical name  :  Cellulose Ethyl Ether 
 
Structural Formula : 
 
 
 
Fig : 8 Structure of Ethyl Cellulose 
 
 
Functional Category: 
 
             Coating agent, flavoring fixative, tablet binders, tablet filler, 
viscosity increasing agent. 
 
Description: 
    
             Ethyl cellulose is a tasteless, free flowing, white to light tan 
colored powder. 
 
7.4.1 Typical Properties: 
 
Density (bulk)  
         0.4g/cm3 
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Solubility: 
 
        It is practically insoluble in glycerin, propylene glycol and 
water. 
 
Specific Gravity: 
         1.12-1.15g/cm3 
 
Stability: 
          It is stable, slightly hygroscopic material, chemically resistant 
to alkalis. It is subject to oxidative degradation in presence of 
sunlight or UV light at elevated temperatures. 
 
Incompatibility: 
 
        Incompatible with paraffin wax and microcrystalline wax. 
 
7.4.2 Application: 
 
¾ Ethyl Cellulose is widely used in oral and topical 
pharmaceutical formulation. 
¾ It is used as a hydrophobic coating agent for tablets and 
granules. 
¾ It is used to modify the release of a drug  
¾ It is used to mask an unpleasant taste. 
¾ It is used to improve stability of a formulation. 
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8. ANALYTICAL METHODS 
 
8.1 PROCEDURE FOR STANDARD GRAPH  OF  
NICORANDIL 
 
Preparation of stock solution 
 
        100mg pure drug (Nicorandil-API) is dissolved in deionized 
water and made up to 100ml in a standard flask .From this, 10 ml of  
the drug solution is withdrawn  and made up to 100ml with 
deionized water in a standard flask, to give the stock solution 
100µg/ml. 
 
         From this solution, pipette out 1.0, 2.0, 3.0, 4.0 and 5.0 ml, 
which are transferred into a series of 10 ml volumetric flasks and the 
final volume was brought up to 10ml with deionized water to get 
concentrations of 10, 20, 30, 40, 50 µg /ml. A blank was also 
prepared. The absorbance was measured at 262nm and the standard 
graph was plotted concentration (µg/ml) Vs Absorbance. The results 
were given in Table 7 and Fig 8. 
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TABLE 7 : STANDARD GRAPH OF NICORANDIL 
 
Concentration(µg/ml) Absorbance at 262 nm 
0 0.0000 
10 0.1616 
20 0.3339 
30 0.5033 
40 0.6621 
50 0.8282 
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 Fig :8  Standard Graph of Nicorandil 
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8.2 FT-IR COMPATIBILITY STUDIES 
 
The drug (API) and the polymers used were subjected to FT-
IR individually and in combination with polymers and checked for 
compatibility. The results were tested for incompatibility. 
  
 One of the requirements for the selection of suitable polymers 
or carriers for pharmaceutical formulation is its compatibility. 
Therefore in the present work a compatibility study was done by 
using Infra Red spectroscopy (IR) to find out if there is any possible  
chemical interaction between nicorandil and the polymers (carbopol-
934, PVA, PVP and Ethyl cellulose). 
 
IR spectral analysis  
 Weighed amount of the drug (3mg) was mixed thoroughly 
with 100mg of potassium bromide (dried at 40° -50° C) which was 
then compressed under 10 ton pressure in a hydraulic press to form a 
pellet which was then scanned from 4000 - 400-1cm using FT-IR 410 
PC spectrophotometer. The same procedure was repeated for 
polymers and formulations. The IR spectrum of nicorandil was 
compared with the IR spectrum of nicorandil and polymers. (Fig 10-
15). 
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Fig :10  IR Spectrum of Nicorandil (API) 
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Fig :11  IR Spectrum of Nicorandil (API) and Carbopol 934 
 
 
 
Fig :12  IR Spectrum of Nicorandil (API) and PVP 
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Fig :14  IR Spectrum of Nicorandil (API) and PVA 
 
 
 
Fig :15  IR Spectrum of Nicorandil (API) and EC 
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9. EXPERIMENTAL METHODOLOGY 
 
            Hypertension and angina pectoris, the most common 
cardiovascular diseases, require constant monitoring. Potassium 
channel openers are presently considered an important class of drugs 
for hypertension and angina pectoris. The first therapeutic drug 
shown to possess ability to hyperpolarize smooth muscle cell 
membranes is nicorandil, a potent coronary vasodilator. Nicorandil is 
one of the emerging molecules in the case of hypertension and 
angina, successful treatment means maintenance of blood pressure at 
a normal physiological level, for which a constant and uniform 
supply of drug is desired. A novel drug delivery for the formulation 
of buccal tablet of Nicorandil by using polymers such as Carbopol 
934 and PVP, which has good mucoadhesive properties, is 
developed by direct compression method. 
 
Effect of backing layer on buccal tablet 
 
Ethyl cellulose is used as backing layer, on one side of the 
buccal tablet to promote unidirectional release. In the absence of 
backing layer, some of the drug released escapes into the oral cavity; 
hence total mucosal drug release will be affected. 
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9.1 PROCEDURE FOR PREPARATION OF NICORANDIL 
BUCCAL TABLETS BY DIRECT COMPRESSION METHOD 
 
Method I 
Respective amount of the drug and polymers were blended 
together thoroughly in a mortar. Other excipients were added to this 
mixture and the final mixture subjected to direct compression in a 
single punch Tablet Punching machine. A suitable backing layer was 
coated on the back side of the tablet, to provide unidirectional 
release. 
 
Table : 8  Composition and formulation code of various buccal 
tablets prepared by Method I 
 
Formulation 
ingredients 
F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
F4 
(mg) 
F5 
(mg) 
Nicorandil 3 3 3 5 3 
Carbopol-934 120 120 100 120 120 
PVP 80 80 80 80 0 
PVA 0 0 50 0 0 
Magnesium Stearate q.s q.s q.s q.s q.s 
Mannitol q.s q.s q.s q.s q.s 
β cyclodextrin 2 2 2 2 2 
Ethyl Cellulose Coated as Backing layer 
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Method II 
         Bilayered tablets were prepared, core tablet compressed with a 
backing layer. Core tablet was prepared by compressing the drug 
with suitable ratios of polymers. Then, a backing layer of polymer is 
compressed onto the core tablet. The blended powder was then 
lightly compressed on 8mm flat faced punch using single punch 
tablet compression machine. 
         The upper punch was then removed and backing layer material 
was added over it and finally compressed at a constant compression 
force. 
 
Table : 9 Composition and formulation code of various tablets 
prepared by Method II 
 
Formulation ingredients B1 (mg) 
B2 
(mg) 
B3 
(mg) 
B4 
(mg) 
Nicorandil 3 5 3 3 
Carbopol-934 120 120 80 20 
PVP 80 80 20 180 
PVA 0 0 0 0 
Magnesium Stearate q.s q.s q.s q.s 
Mannitol q.s q.s q.s q.s 
β cyclodextrin 2 2 2 2 
Backing Layer 
Ethyl cellulose 30 30 30 30 
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9.2  EVALUATION OF NICORANDIL-BUCCAL TABLETS 
9.2.1 Weight variation test 
 
To study weight variation, 20 tablets of each formulation were 
weighed using an electronic balance, and the test was performed 
according to the official method as in BP. The weight variation 
allowed as per USP limit is 7.5%. The weights of individual tablets 
were within the BP limits. The results were shown in Table 10. 
 
Table : 10    Weight variation of formulated Nicorandil buccal 
tablets 
 
Formulation 
code 
Wt Range of 
20 tabs (mg) 
Average weight 
(mg) 
Limit range 
 (±7.5%) 
F1 247-260 253 245.5-260.5 
F2 315-326 321 313.5-328.5 
F3 243-257 250 242.5-257.5 
F4 256-268 263 255.5-270.5 
F5 229-242 236 228.5-243.5 
B1 279-291 285 277.5-292.5 
B2 282-293 288 280.5-295.5 
B3 198-212 205 197.5-212.5 
B4 269-283 276 268.5-283.5 
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9.2.2 Drug content assay 
 
The prepared buccal tablets containing Nicorandil was tested 
for drug content uniformity as per specifications of IP 1996. Five 
tablets were weighed individually, and the drug was extracted in 
water. The drug content was determined as described. An accurately 
weighed amount of powdered nicorandil granules (100 mg) was 
extracted with water and the solution was filtered through 0.45-µ 
membrane (New Delhi, India). The absorbance was measured at 262 
nm after suitable dilution. The results were shown in Table  11.    
 
Table : 11 . Drug content uniformity of various nicorandil  
buccal tablets 
 
Amount of Nicorandil content 
per buccal tablet Formulation 
 
Absorbance 
(262nm) Amt (in mg) Percentage Purity 
F1 0.228 8.703 87.03 
F2 0.256 9.713 97.71 
F3 0.238 9.083 90.84 
F4 0.241 9.198 91.98 
F5 0.231 8.816 88.16 
B1 0.244 9.313 93.13 
B2 0.251 9.579 95.81 
B3 0.254 9.694 96.94 
B4 0.231 8.816 88.17 
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9.2.3. Thickness and diameter 
 
Uniform compression force and volume of die fill leads to 
uniform thickness. From each batch, 3 buccal tablets were taken and 
checked with a electronic thick-ness gauge (Mitutoyo, New Delhi, 
India). Standard deviation was calculated and the results were given 
in Table 12  . .Similarly, three tablets were taken and checked for 
diameter using vernier, the results were given in Table 12. 
 
9.2.4 Hardness  
  
For each formulation, the hardness of 3 tablets were 
determined using the Monsanto hardness tester (Cad-mach, 
Ahmedabad, India), and the average was calculated and recorded in 
Table 12. 
 
 
9.2.5 Friability 
 
For each formulation, the friability of 10 tablets were 
determined using the Roche friabilator (Camp-bell Electronics, 
Mumbai, India), respectively (Table 12). 
 
% Friability =   Loss of weight x 100 
                                  Initial weight 
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Table :12 . Thickness, hardness and % friability of  various 
formulated nicorandil buccal tablets 
 
 
Sl. 
No. 
Formulation 
code 
Thickness 
(mm) 
Hardness 
(kg/cm2)  
Friability 
 (%) 
1 F1 2.42 ± 0.2 7.5 ± 0.14 0.75  
2 F2 2.93 ± 0.1 6.5 ± 0.09 0.69 
3 F3 2.14 ± 0.3 8.5 ± 0.11 0.40  
4 F4 2.25 ± 0.1 7.5 ± 0.13 0.48  
5 F5 1.83 ± 0.3 6.5 ± 0.18 0.13  
6 B1 2.22 ± 0.2 8.0 ± 0.12 0.17  
7 B2 2.27 ± 0.2 7.0 ± 0.23 0.28  
8 B3 2.01 ± 0.1 8.5 ± 0.14 1.63  
9 B4 2.73 ± 0.2 9.0 ± 0.11 0.76  
n=3; ± Sd 
 
 
9.3 FT-IR compatibility studies 
 
The drug (API) and the polymers used were subjected to FT-
IR individually and in combination with polymers and checked for 
compatibility. The results were tested for incompatibility. 
  
 One of the requirements for the selection of suitable polymers 
or carriers for pharmaceutical formulation is its compatibility. 
Therefore in the present work a compatibility study was done by 
using Infra Red spectroscopy (IR) to find out if there is any possible  
chemical interaction between nicorandil and the polymers (carbopol-
934,PVA,PVP and Ethyl cellulose). 
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IR spectral analysis  
 Weighed amount of the drug (3mg) was mixed thoroughly 
with 100mg of potassium bromide (dried at 40° -50° C) which was 
then compressed under 10 ton pressure in a hydraulic press to form a 
pellet which was then scanned from 4000 - 400-1cm using FT-IR 410 
PC spectrophotometer. The same procedure was repeated for 
polymers and formulations. The IR spectrum of nicorandil was 
compared with the IR spectrum of formulation. The IR spectrum of 
the formulations F1-F5 and B1-B4 are given in Fig 16-24. 
 
 
Fig :16    IR SPECTRUM OF F1 
 
*F1- Composition: Nicorandil  3mg, CP 120mg,  PVP  80mg, EC 
qs 
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Fig : 17    IR SPECTRUM OF F2 
*F2- Composition:Nicorandil  3mg, CP   100mg, PVP  80mg, EC 
q.s 
 
 
Fig :18   IR SPECTRUM OF F3 
*F3- Composition: Nicorandil 3mg, CP  120mg, PVP  80mg, 
PVA 50mg, EC q.s 
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Fig :19   IR SPECTRUM OF F4 
*F4- Composition: Nicorandil  5mg, CP  120mg,  PVP 80mg, EC 
q.s 
 
 
Fig : 20    IR SPECTRUM OF F5 
*F5- Composition: Nicorandil 3mg, CP  120mg, EC q.s. 
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Fig : 21    IR SPECTRUM OF B1 
*  B1- Composition: Nicorandil 3mg, CP  120mg, PVP 80mg,  
EC 30mg 
 
 
 
 
 
 
Fig :22   IR SPECTRUM OF B2 
* B2- Composition: Nicorandil 3mg, CP 120mg, PVP 80mg, EC 
q.s 
 
 
 
 
Chapter IX              Experimental Methodology
    
 
 
- 76 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 23    IR SPECTRUM OF B3 
*B3 - Composition: Nicorandil 3mg, CP 80mg, PVP 20mg, EC 
q.s 
 
 
Fig : 24    IR SPECTRUM OF B4 
*B4- Composition: Nicorandil 3mg, CP  20mg, PVP 180mg, EC 
q.s 
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9.4 IN-VITRO DRUG RELEASE STUDIES  
 
The in-vitro dissolution studies were carried out using USP 
apparatus type II (Tab-Machines, Mumbai, India) at 75 rpm. The 
dissolution medium consisted for the phosphate buffer pH 6.8 (250 
ml), maintained at 37°C ± 0.5°C. The formulated tablets containing 
Nicorandil equivalent to 3mg and 5mg were taken and kept in the 
dissolution medium and the paddle type stirrer was adjusted to 75 
rpm. 5ml aliquot dissolution media was withdrawn at intervals and 
volume withdrawn was replaced with fresh quantity of dissolution 
media. The drug release at different time intervals (1h, 2h, 3h, 4h, 
5h, 6h, 7h, and 8h) was measured by diode array UV-visible 
spectrophotometer at 262 nm. 
 
The percentage of Nicorandil dissolved at various time 
intervals was calculated and plotted against time. The results are 
shown in Tables 13-21 and Fig 25-33. 
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Table : 13  Dissolution profile of the buccal formulation F1* at 
pH 6.8 at different time intervals 
 
F1 
Time 
(hr) 
Absorbance
(262nm) 
C 
(µ/ml) 
C 
(mg/250ml)
Cumulative 
%release 
1 0.05 3.5 0.875 29.17± 0.39 
2 0.055 4.2 1.05 35.00 ± 0.74 
3 0.0682 4.8 1.2 40.00 ± 0.46 
4 0.0754 5.3 1.325 44.17 ± 0.62 
5 0.0781 5.5 1.375 45.83 ± 0.86 
6 0.0824 5.8 1.45 48.33 ± 1.2 
7 0.0931 6.1 1.525 50.83 ± 0.78 
8 0.1276 8.8 2.2 73.33 ± 1.34 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 25. Graph showing dissolution profile of F1 
 
*F1- Composition: Nicorandil 3mg, CP 120mg, PVP  80mg, EC 
qs 
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Table :14  Dissolution profile of the buccal formulation F2* at 
pH 6.8 at different time intervals 
 
F2 
Time (hr) 
Absorbance 
(262nm) 
C 
(µ/ml) 
 
C 
(mg/250ml)
 
Cumulative 
%release 
1 0.0158 2.2 0.55 18.33 ± 0.12 
2 0.0475 3.6 0.9 30.00 ± 0.54 
3 0.0695 4.35 1.0875 36.25 ±0.09 
4 0.0721 4.52 1.13 37.67 ±0.86 
5 0.0843 5.34 1.335 44.50 ±1.08 
6 0.0927 5.65 1.4125 47.08 ±0.56 
7 0.1098 6.34 1.585 52.83 ±0.78 
8 0.1134 8.2 2.05 68.33 ±1.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 26. Graph showing dissolution profile of F2 
 
*F2- Composition: Nicorandil 3mg, CP   100mg, PVP 80mg, EC 
q.s 
 
 
 
Dissolution Profile of F2
0
10
20
30
40
50
60
70
80
0 1 2 3 4 5 6 7 8 9
Time (in hr)
%
 C
um
ul
at
iv
e 
Re
le
as
e
F2
Chapter IX              Experimental Methodology
    
 
 
- 80 - 
 
Table : 15 .Dissolution profile of the buccal formulation F3* at 
pH 6.8 at different time intervals 
 
F3 
Time (hr) 
Absorbance 
(262nm) 
C  
(µ/ml) 
 
C 
(mg/250ml
) 
 
Cumulative 
%release 
1 0.0667 4.2 1.05 35.00 ± 0.45 
2 0.116 7.5 1.875 62.50 ± 0.51 
3 0.128 8.4 2.1 70.00 ± 1.52 
4 0.1325 8.6 2.15 71.67 ± 1.09 
5 0.1384 8.8 2.2 73.33 ± 0.86 
6 0.1412 9.1 2.275 75.83 ± 0.77 
7 0.1467 9.4 2.35 78.33 ± 0.64 
8 0.1481 9.7 2.425 80.83 ± 0.93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 27. Graph showing dissolution profile of F3 
 
*F3- Composition: Nicorandil 3mg, CP  120mg,  PVP  80mg, 
PVA 50mg, EC q.s 
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Table :16. Dissolution profile of the buccal formulation F4* at 
pH 6.8 at different time intervals 
 
 
F4 
Time (hr) 
Absorbance 
(262nm) C (µ/ml) 
C 
(mg/250ml) 
Cumulative 
%release 
1 0.1097 5.8 1.45 29.00 ± 0.33 
2 0.1102 6.2 1.55 31.00 ± 0.65 
3 0.1256 7.8 1.95 39.00 ± 0.58 
4 0.1433 9.8 2.45 49.00 ± 0.42 
5 0.1642 11.1 2.78 55.50 ± 0.96 
6 0.2068 12.9 3.23 64.50 ± 1.21 
7 0.2136 14.3 3.58 71.50 ± 1.10 
8 0.2534 15.8 3.95 79.00 ± 0.52 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 28. Graph showing dissolution profile of F4 
 
*F4:  Composition: Nicorandil 5mg, CP  120mg,  PVP 80mg, EC 
q.s 
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Table : 17 Dissolution profile of the buccal formulation F5* at 
pH 6.8 at different time intervals 
 
F5 
Time 
(hr) 
Absorbance 
(262nm) 
C 
(µ/ml)
C 
(mg/250ml)
Cumulative 
%release 
1 0.0361 2.2 0.55 18.33 ± 0.48 
2 0.0529 2.5 0.625 20.83 ± 0.89 
3 0.0762 3.8 0.95 31.66 ± 0.73 
4 0.0893 3.9 0.975 32.50 ± 1.3 
5 0.0912 4.1 1.025 34.17 ± 0.65 
6 0.0936 4.7 1.175 39.17 ± 0.33 
7 0.1243 7.5 1.875 62.50 ± 0.55 
8 0.1336 8.9 2.225 68.17 ± 0.68 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig :29. Graph showing dissolution profile of F5 
 
*F5- Composition: Nicorandil 3mg, CP   120mg, EC q.s. 
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Table : 18. Dissolution profile of the buccal formulation B1* at 
pH 6.8 at different time intervals 
 
B1 
Time (hr) 
Absorbance 
(262nm) 
C 
(µ/ml) 
C 
(mg/250ml)
Cumulative 
%release 
1 0.0391 2.2 0.55 18.33 ± 0.44 
2 0.0723 3.6 0.9 30.00 ± 0.72 
3 0.0942 4.8 1.2 40.00 ± 0.12 
4 0.1288 6.8 1.7 56.67 ± 0.34 
5 0.1312 7.1 1.775 59.17 ± 0.32 
6 0.1342 7.8 1.95 65.00 ± 0.88 
7 0.1377 8.6 2.15 71.67 ± 0.81 
8 0.1413 9.1 2.275 75.83 ± 1.20 
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Fig : 30  Graph showing dissolution profile of B1 
 
*  B1- Composition: Nicorandil 3mg, CP  120mg,  PVP 80mg, 
EC 30mg 
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Table :19  Dissolution profile of the buccal formulation B2* at 
pH 6.8 at different time intervals 
 
Time (hr) Absorbance (262nm) 
C 
(µ/ml)
C 
(mg/250ml)
Cumulative 
%release 
1 0.0984 6.7 1.675 33.50 ± 0.73 
2 0.1527 9.8 2.45 49.00 ± 0.88 
3 0.2074 12.8 3.2 64.00 ± 0.34 
4 0.2169 14.7 3.675 73.50 ± 0.23 
5 0.2272 15.2 3.8 76.00 ± 0.56 
6 0.2342 16.1 4.025 80.50 ± 0.78 
7 0.2481 16.7 4.175 83.50 ± 1.07 
8 0.2711 17.4 4.35 87.00 ± 1.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 31  Graph showing dissolution profile of B2 
 
* B2- Composition: Nicorandil  3mg, CP  120mg, PVP  80mg, 
 EC q.s 
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Table :20  Dissolution profile of the buccal formulation B3* at 
pH 6.8 at different time intervals 
 
Time  
(hr) 
Absorbance 
(262nm) 
C 
(µ/ml) 
C 
(mg/250ml) 
Cumulative 
%release 
1 0.0323 2.1 0.525 17.50 ± 0.68 
2 0.1288 7.6 1.9 63.33 ± 0.87 
3 0.1432 7.7 1.925 64.17 ± 0.32 
4 0.1664 8.1 2.025 67.50 ± 0.64 
5 0.1695 8.2 2.05 68.33 ± 0.95 
6 0.1723 9.6 2.4 80.00 ± 1.22 
7 0.1746 9.7 2.425 80.83 ± 0.43 
8 0.1792 9.8 2.45 81.67 ± 0.69 
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Fig : 32. Graph showing dissolution profile of B3 
 
*B3 - Composition: Nicorandil 3mg, CP  80mg, PVP  20mg, EC 
q.s 
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Table : 21. Dissolution profile of the buccal formulation B4* at 
pH 6.8 at different time intervals 
 
 
Time 
 (hr) 
Absorbance 
(262nm) 
C 
 (µ/ml) 
C  
(mg/250ml) 
Cumulative 
%release 
1 0.8765 5.8 1.45 48.33 ± 0.70 
2 0.9504 6.3 1.575 52.50 ± 0.62 
3 0.1092 7.2 1.8 60.00 ± 0.85 
4 0.1148 7.6 1.9 63.33 ± 1.40 
5 0.1151 8.1 2.025 67.50 ± 0.87 
6 0.1285 8.5 2.125 70.83 ± 0.61 
7 0.1342 8.8 2.2 73.33 ± 0.45 
8 0.1547 9.2 2.3 76.67 ± 0.72 
 
 
 
 
 
 
 
 
Fig : 33   Graph showing dissolution profile of B4 
 
*B4- Composition: Nicorandil 3mg, CP  20mg,  PVP 180mg, EC 
q.s 
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Fig : 34    Comparative graph showing the invitro release of 
nicorandil buccal tablets of F1, F2, F3, F4 and F5 
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Fig : 35   Comparative graph showing the invitro release of 
nicorandil buccal tablets of B1,B2,B3 and B4 
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9.5 DISSOLUTION KINETICS OF DRUG RELEASE  
 
 To study the release kinetics, data obtained from in vitro drug 
release studies were plotted in various kinetic models: Zero order 
(Equation 1) as cumulative amount of drug released vs time, First 
order (Equation 2) as log cumulative percentage of drug remaining 
vs time, Higuchi’s model (Equation 3) as cumulative percentage of 
drug released vs square root of time and Korsmeyer’s (Equation 4) 
log cumulative percentage of drug released vs. log time 
                  C = Kº t.      (Equation 1) 
 
 Where Kº is the zero-order rate constant expressed in units of 
concentration/time and t is the time in hours. A graph of 
concentration vs time would yield a straight line with a slope equal 
to K0 and intercept the origin of the axes. 
   LogC = LogCo−kt/2:303         (Equation 2) 
  
 Where C0 is the initial concentration of drug, k is the first 
order constant, and t is the time. 
   Q = Kt ½                             (Equation 3)  
 Where K is the constant reflecting the design variables of the 
system and t is the time in hours. Hence, drug release rate is 
proportional to the reciprocal of the square root of time. 
 Drug release were plotted in Korsmeyer et al’s equation 
(Equation 4) as log cumulative percentage of drug released vs log 
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time, and the exponent n was calculated through the slope of the 
straight line. 
                              Mt/M∞ = Ktn                           (Equation 4) 
 Where Mt/M∞ is the fractional solute release, t is the release 
time, K is a kinetic constant. 
 
Table: 22  Drug release kinetics for Nicorandil buccal Tablets 
Formulation 
code 
Zero 
Order R2 
First 
Order R2
Higuchi's 
Plot R2 
Korsmeyer's 
Plot R2 
F1 0.984 0.973 0.996 0.991 
F2 0.983 0.943 0.988 0.977 
F3 0.966 0.992 0.993 0.942 
F4 0.953 0.952 0.959 0.871 
F5 0.966 0.990 0.990 0.925 
B1 0.969 0.977 0.986 0.937 
B2 0.834 0.843 0.994 0.956 
B3 0.976 0.976 0.967 0.974 
B4 0.972 0.956 0.984 0.949 
 
 
        In vitro data obtained for buccal tablets containing nicorandil 
were used to determine the dissolution kinetics. The drug release 
data of nicorandil  were fitted to models representing Zero order 
(cumulative amount of drug released vs time), First order (log 
cumulative percentage of drug remaining vs time), Higuchi’s 
(cumulative percentage of drug released vs square root of time), and 
Chapter IX              Experimental Methodology
    
 
 
- 90 - 
 
Korsmeyer’s equation (log cumulative percentage of drug released 
vs log time) kinetics to know the release mechanisms. The data were 
processed for regression analysis using MS-EXCEL statistical 
functions. These data indicated that the drug release followed the 
diffusion controlled model as described by Higuchi’s square root of 
time equation. 
 
 The chart of the formulation having best release 
characteristics in each method was plotted (Fig. 36-43). The 
formulation showing good release kinetics was found to be F4 
(Method I) and B2 (Method II). 
 
F4 
  
Chart Title
y = -8.7833x + 88.633
R2 = 0.9529
0.00
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Linear (drug unreleased)
 
Fig :36  Graph showing first order kinetics of F4 buccal tablets. 
*F4- Composition: Nicorandil 5mg, CP  120mg, PVP 80mg, EC 
q.s 
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Fig : 37 . Graph showing zero order kinetics of F4 buccal tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 38  Graph showing kosermeyer order kinetics of F4 buccal 
tablets 
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Fig : 39   Graph showing Higucchi’s kinetics of F4 buccal tablets 
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Fig : 40   Graph showing first order kinetics of B2 buccal tablets 
(* B2- Composition: Nicorandil 3mg, CP 120mg, PVP 80mg,  
EC q.s) 
 
 
Chart Title
y = -0.2219x + 2.0863
R2 = 0.8706
0.00
0.50
1.00
1.50
2.00
2.50
0.00 0.50 1.00 1.50 2.00 2.50 3.00
log of drug unreleased
Linear (log of drug
unreleased)
Chapter IX              Experimental Methodology
    
 
 
- 93 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 41   Graph showing zero order kinetics of B2 buccal tablets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 42   Graph showing zero order kinetics of B2 buccal tablets. 
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Fig : 43  Graph showing zero order kinetics of B2 buccal tablets 
 
 
9.6  SWELLING STUDIES AND SWELLING INDEX 
  
The tablets of each formulation were weighed individually (W1) and 
placed separately in Petri dishes containing 2% agar gel. 
 
At regular intervals (1h, 2h, 3h, 4h, 5h, 6h, 7h and 8h), the tablets 
were removed from Petri dishes and excess water removed carefully 
using filter paper. 
 
Swollen tablets are reweighed (W2), the swelling index calculated 
using the formula. (Table 23, Fig. 44)  
 
Swelling Index (S.I) = (W1-W2) / W1 
Percentage Swelling = (W1-W2) / W1   X 100 
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10. RESULTS AND DISCUSSION 
  
 
            The aim of the present study was to develop buccal tablets, 
containing Nicorandil, using various bioadhesive polymers such as 
Carbopol 934 (CP), Polyvinylpyrrolidone (PVP), Polyvinylalcohol 
(PVA) and Ethylcellulose (EC), for the prolonged release of the drug 
nicorandil. In this work, Nicorandil is selected as an ideal drug 
candidate because of its potent coronary vasodilator activity. Also, it 
possess’ the ability to hyperpolarize smooth muscle cell membrane 
and it is one of the emerging molecules in the treatment of 
hypertension and angina. 
 
10.1 FORMULATION OF BUCCAL TABLETS 
           In the present study, an attempt was made to prepare different 
formulations of mucoretentive drug delivery system, using various 
bioadhesive polymers. There are two methods adapted for 
preparation of buccal tablets. In the first method (Table 8), the core 
tablet is prepared by direct compression of nicorandil, PVP, PVA 
and EC is coated as a backing layer [F1, F2, F3, F4, and F5] and in 
the second method (Table 9), various bilayered tablets were prepared 
using nicorandil, CP and PVP as core tablet and EC compressed over 
it as a backing layer [B1, B2, B3 and B4]. The prepared various 
tablets were made to undergo physiochemical evaluation, 
incompatibility studies, in vitro drug release and in vitro dissolution 
kinetics. 
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10.2 COMPATIBILITY STUDIES 
           The compatibility studies of the drug and the polymer and 
various formulations were estimated by using FT-IR [Jasco-FT-IR 
8201 PC]. The  IR Spectrum of the pure drug (Nicorandil-API) 
showed a few intense peaks at 3739.5 cm-1, 1631.48 cm-1, 3078.8 
cm-1, 3234.04 cm-1, 1286.09 cm-1, 999.94 cm-1  which were 
characteristic for the drug and similar peaks were observed in all 
tablet formulations. From the spectra, shown in the Fig. 16-24, we 
found that there was no significant incompatibility between the pure 
drug, polymer and in all nine formulations, indicating the stability of 
the drug in these formulations. 
 
10.3 EVALUATION OF PHYSIOCHEMICAL PARAMETERS 
           Various physiochemical parameters such as thickness, weight 
variation, content uniformity, friability, hardness, thickness and 
swelling studies were studied on the prepared buccal tablets. The 
thickness of all the tablets fall in the range of 1.83± 0.3 to 2.42± 0.2 
mm [F1, F2, F3, F4 and F5] and 2.01± 0.1 to 2.73± 0.02 [B1, B2, B3 
and B4]. The readings (thickness) of all the formulations fell in the 
acceptable range of USP standards. The values of other parameters 
such as weight variation, hardness, drug content uniformity and 
friability are within the acceptable range. The average percentage 
deviation of 20 prepared buccal tablets was less than ±5% 
           
The drug content of various buccal tablets [F1-F5 and B1-B4] 
ranged from 87.03-97.71%. The hardness and percentage friability 
of the prepared buccal tablets ranged from 6.5± 0.09 to 9.0± 0.11 
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kg/cm² and 0.61% to 0.13%, respectively. All the values of the 
physicochemical parameters are shown in Table 12. 
 
           The percentage swelling for the buccal tablets F1, F2, F3, F4 
and F5 were calculated and found to be in the range of 34.5 to 
49.2%, with formulation F4 showing a maximum of 49.2%. The 
formulations B1, B2, B3 and B4, the percentage swelling was found 
to be in the range of 9.4-26.7%, with formulation B3 showing 
maximum swelling of 26.7%. From the results of the swelling 
studies, the tablets did not show any appreciable change in shape and 
nature during the 8 h of study. The comparative percentage swelling 
for various prepared buccal tablets was in the order of F4> F2> F3> 
F1> F5 and B3> B4> B1> B2 and the data is shown Table 23 and 
Fig 44. 
 
10.4 IN VITRO DISSOLUTION STUDY 
 
         The in vitro dissolution study of the prepared buccal tablets 
[nine formulations including F1, F2, F3, F4, F5, B1, B2, B3 and B4 
was carried out using phosphate buffer pH 6.8 at temperature 37± 
0.5ºC at 75 rpm in a dissolution apparatus (Electrolab TDT-08L. 
Chennai ). The data of the in vitro release of all formulation are 
given in Tables 13 to 21 and the dissolution profiles are shown in 
Fig 25 to 33. 
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          Among the nine formulations, F3 (Comp. : Nicorandil-3mg, 
CP- 100mg, PVP- 80mg and PVA- 50mg) showed maximum drug 
release of 80.83± 0.93% and B2 (Comp. :Nicorandil_5mg, 
CP_120mg, PVP_80mg) exhibited highest drug release of 87.0± 
1.03%. From this dissolution studies, we found that F3 showed 
maximum drug release due to high wettability of the polymer PVP 
and PVA. The buccal tablet F5 showed lowest release of 68.17± 
0.68% due to absence of PVP and PVA.       
 
10.5 DRUG RELEASE KINETICS 
         The mechanism of drug release from all the nine formulations 
was determined using four different in vitro kinetic models such as 
first order (log cumulative percentage of drug remaining vs time), 
Higuchi’s (cumulative percentage of drug released vs square root of 
time) and Kosermeyer et al’s (log cumulative percentage of drug 
released vs log time) equations along with zero order (cumulative 
amount of drug released vs time) pattern. The release rate kinetics 
for all prepared buccal tablets is shown in Table 22. In our 
experiments,  the in vitro release profiles of drug from all the 
formulations could be best expressed by Higuchi’s equation, as the 
plots showed high linearity (R² =0.9707 to 0.9967) and the release 
kinetics of  the best formulation (F4 and B2) were studied and the 
release profile are shown in Fig 36-39 and 40-43, respectively. 
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11. SUMMARY AND CONCLUSION 
 
Drug delivery within the oral cavity may be summarized 
under buccal, sublingual and local delivery. Among the three routes 
of drug delivery within the oral cavity, sublingual and buccal are 
found to be the most effective. Here we have selected buccal drug 
delivery system because unlike sublingual, buccal is suitable for oral 
transmucosal delivery system. Buccal is a more preferred route, for 
the systemic transmucosal drug delivery. The reason that the buccal 
mucosa has an expanse of smooth muscle and relatively immobile 
mucosa which makes it a more desirable region for drugs used in 
oral mucosal drug delivery. Thus, the buccal mucosa is more filled 
for delivery of less permeable molecules and perhaps peptide drugs.  
 
In this present study, nine different buccal tablets containing  
nicorandil, using various bioadhesive polymers such as CP, PVP, 
PVA and EC (backing layer), by two different methods. All the nine 
formulations were used for the determination of physicochemical 
evaluations, in vitro drug release and in vitro dissolution kinetics.  
 
From this work, we conclude that F3 (Content: Nicorandil 
3mg, CP 100mg, PVP 80mg and PVA 50mg) and B2 (Content: 
Nicorandil 5mg, CP 120mg, PVP 80mg) were found to be ideal 
buccal tablets, with the highest percentage release of 80.83± 0.93% 
and 87.0± 1.03%, respectively and we also found that the ideal 
bioadhesive carriers are PVP and PVA, because of high wettability 
of the mucous membrane of the buccal area. Further studies can be 
done to improve the buccal delivery system by in vivo permeation 
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studies. They can be employed to examine drug transport across 
buccal tissues from animal models. Buccal cell cultures have also 
been suggested as useful in vitro models for buccal drug permeation 
and metabolism. In vivo methods were first developed by Beckett 
and Triggs with buccal absorption test, with which the kinetics of 
drug absorption was measured. The drawbacks of this method 
include salivary dilution of the drug, accidental swallowing a portion 
of sample solution, and the inability to localize the drug solution 
within a specific site. Pharmacokinetic parameters such as 
bioavailability can then be calculated from the plasma concentration 
vs time profile.  
 
The buccal mucosa offers several advantages for effective 
drug delivery. The mucosa is well supplied with both vascular and 
lymphatic drainage, first pass metabolism and in the liver and 
presystemic elimination in the gastrointestinal tract are avoided.  
 
          The area is well suited for a retentive device and appears to be 
acceptable to the patient. With the right dosage form design and 
formulation, the permeability and the local environment of the 
mucosa can be controlled and manipulated in order to accommodate 
drug permeation. Buccal drug delivery is a promising area with 
continued research, with the aim of systemic delivery of orally 
inefficient drugs as well as an attractive alternative for non–invasive 
delivery of potent peptide and protein drug molecules. Bioadhesive 
studies, animal model and in vivo drug release could be carried out 
to evaluate the performance of prepared buccal tablets of Nicorandil. 
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